Attovia Therapeutics (NASDAQ:ATTO) Now Covered by Lifesci Capital

Research analysts at Lifesci Capital assumed coverage on shares of Attovia Therapeutics (NASDAQ:ATTO) in a report issued on Monday,Benzinga reports. The firm set an “outperform” rating and a $45.00 price target on the stock. Lifesci Capital’s price target would indicate a potential upside of 125.03% from the stock’s previous close.

A number of other research analysts also recently weighed in on ATTO. Morgan Stanley began coverage on shares of Attovia Therapeutics in a research report on Monday. They issued an “overweight” rating and a $39.00 target price for the company. Leerink Partners started coverage on shares of Attovia Therapeutics in a research report on Monday. They set an “outperform” rating and a $52.00 price target on the stock. Royal Bank Of Canada initiated coverage on shares of Attovia Therapeutics in a research note on Monday. They set an “outperform” rating and a $45.00 price objective for the company. Finally, Citigroup started coverage on Attovia Therapeutics in a report on Monday. They issued a “buy” rating and a $30.00 price objective for the company. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Attovia Therapeutics presently has a consensus rating of “Buy” and an average price target of $42.20.

Attovia Therapeutics Trading Down 3.4%

Shares of NASDAQ ATTO traded down $0.70 during midday trading on Monday, reaching $20.00. The company’s stock had a trading volume of 43,722 shares, compared to its average volume of 268,044. Attovia Therapeutics has a fifty-two week low of $16.15 and a fifty-two week high of $24.32.

Insider Activity

In other news, major shareholder Life Sciences Xi L.P. Frazier purchased 588,235 shares of the business’s stock in a transaction on Thursday, August 6th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $9,999,995.00. Following the completion of the purchase, the insider directly owned 6,154,213 shares in the company, valued at $104,621,621. The trade was a 10.57% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Global Strategic Fund I. Venbio acquired 382,352 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was purchased at an average cost of $17.00 per share, with a total value of $6,499,984.00. Following the transaction, the insider owned 4,181,367 shares in the company, valued at approximately $71,083,239. This trade represents a 10.06% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders purchased 2,740,587 shares of company stock valued at $47,269,979.

Institutional Trading of Attovia Therapeutics

A hedge fund recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. lifted its holdings in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 164,358 shares of the company’s stock after acquiring an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 as of its most recent SEC filing.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.